Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of \>= 220 and \<= 450, normal laboratory parameters,~* are willing and able to give informed consent, and~* are able to self-inject or have a designee or healthcare professional who can inject the study medication.~Exclusion:~* History of certain types of cancer, diagnosis of ulcerative colitis,~* female or breast feeding subjects,~* surgical bowel resection(s) with in the past 6 months,~* history of listeria,~* human immunodeficiency virus (HIV),~* central nervous system demyelinating disease or untreated TB,~* history of a poorly controlled medical condition,~* unsuccessful response to infliximab or any anti-TNF agent use in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).